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Development and validation of risk prediction equations to 
estimate future risk of blindness and lower limb amputation 
in patients with diabetes: cohort study
Julia Hippisley-Cox, Carol Coupland 
ABSTRACT
Study queStion
Is it possible to develop and externally validate risk 
prediction equations to estimate the 10 year risk of 
blindness and lower limb amputation in patients with 
diabetes aged 25-84 years?
MethodS
This was a prospective cohort study using routinely 
collected data from general practices in England 
contributing to the QResearch and Clinical Practice 
Research Datalink (CPRD) databases during the study 
period 1998-2014. The equations were developed 
using 763 QResearch practices (n=454 575 patients 
with diabetes) and validated in 254 different 
QResearch practices (n=142 419) and 357 CPRD 
practices (n=206 050). Cox proportional hazards 
models were used to derive separate risk equations for 
blindness and amputation in men and women that 
could be evaluated at 10 years. Measures of calibration 
and discrimination were calculated in the two 
validation cohorts.
Study anSwer and liMitationS
Risk prediction equations to quantify absolute risk of 
blindness and amputation in men and women with 
diabetes have been developed and externally 
validated. In the QResearch derivation cohort, 4822 
new cases of lower limb amputation and 8063 new 
cases of blindness occurred during follow-up. The risk 
equations were well calibrated in both validation 
cohorts. Discrimination was good in men in the 
external CPRD cohort for amputation (D statistic 1.69, 
Harrell’s C statistic 0.77) and blindness (D statistic 
1.40, Harrell’s C statistic 0.73), with similar results in 
women and in the QResearch validation cohort. The 
algorithms are based on variables that patients are 
likely to know or that are routinely recorded in general 
practice computer systems. They can be used to 
identify patients at high risk for prevention or further 
assessment. Limitations include lack of formally 
adjudicated outcomes, information bias, and 
missing data.
what thiS Study addS
Patients with type 1 or type 2 diabetes are at increased 
risk of blindness and amputation but generally do not 
have accurate assessments of the magnitude of their 
individual risks. The new algorithms calculate the 
absolute risk of developing these complications over a 
10 year period in patients with diabetes, taking 
account of their individual risk factors.
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Introduction
Diabetes is associated with macrovascular complica-
tions including an increased risk of coronary heart dis-
ease or stroke and microvascular complications such as 
kidney failure, blindness, and amputation.1-3 Intensive 
control of risk factors such as glycated haemoglobin 
and systolic blood pressure lowers the incidence of 
microvascular disease in type 1 and type 2 diabetes.2 4-6 
Tight control of blood parameters is the cornerstone 
of national guidance, national audits, and quality 
improvement incentives schemes.3 7-9 However, patients 
need good quality information on how likely they are to 
develop complications and the expected risks and ben-
efits from interventions to reduce the risk, as very few 
patients are able to quantify this accurately.10 Guide-
lines for cardiovascular disease recommend the use of 
calculators such as QRISK2 to estimate the absolute risk 
of cardiovascular disease while taking account of 
patients’ characteristics.7  Although QRISK2 and related 
tools can be used to assess individualised absolute risk 
of cardiovascular disease, stroke, and kidney failure in 
patients with diabetes,11-13 no tools are available to cal-
culate the risk of other complications such as amputa-
tion or blindness. This is important because these are 
the complications that patients with diabetes fear most 
and that most impair their quality of life.14 They are also 
the complications for which patients are most likely to 
overestimate their risk and overestimate the benefits of 
intensive treatment.10
The UK Prospective Diabetes Study (UKPDS) is a 
source of information on the incidence of amputation 
and blindness, based on a cohort that originated from a 
trial of 5102 patients aged 25-65 with newly diagnosed 
WhAT IS knoWn on ThIS TopIC
Patients with type 1 or type 2 diabetes are at increased risk of blindness and 
amputation but generally do not have an accurate assessment of the magnitude of 
their individual risk
WhAT ThIS pApeR AddS
New risk prediction algorithms for blindness and amputation have been developed 
and externally validated
These calculate the absolute risk of developing these complications over a 10 year 
period in patients with diabetes, taking account of their individual risk factors
The web calculator to calculate the absolute risk of complications among patients 
with diabetes is available at qdiabetes.org/amputation-blindness/index.php
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type 2 diabetes recruited between 1977 and 1991 and fol-
lowed up until 1997.5 However, very few patients in the 
cohort developed blindness (n=116) or needed amputa-
tion (n=45) during follow-up.1 6 Also, the generalisabil-
ity of the cohort is limited because of its historical 
nature and exclusion of people aged over 65 and those 
with various comorbidities.
We aimed to derive and externally validate risk pre-
diction equations to quantify absolute 10 year risks of 
blindness and amputation in patients with diabetes by 
using variables recorded in their primary care elec-
tronic record. Our intention was to provide a readily 
accessible method to quantify an individual patient’s 
absolute risks of blindness and amputation to complete 
a risk profile for patients with diabetes. This informa-
tion could be used to provide better information for 
patients and doctors and to prioritise those patients at 
the highest levels of risk to inform treatment decisions 
and for closer management of modifiable risk factors.
Methods
Study design and data source
We did a cohort study using the UK QResearch database 
(version 39, www.qresearch.org) to derive and validate 
the risk equations in a large population of primary care 
patients with diabetes. We also carried out an external 
validation using the Clinical Practice Research Datalink 
(CPRD) database. QResearch is a continually updated, 
patient level, pseudonymised database with data 
extending back to 1989. It includes clinical and demo-
graphic data from more than 1000 general practices 
covering a population of more than 20 million patients, 
collected in the course of routine healthcare. The pri-
mary care data include demographic information, diag-
noses, prescriptions, referrals, laboratory results, and 
clinical values. Diagnoses, symptoms, and clinical val-
ues are recorded using the Read code classification.15 
QResearch has been used for a wide range of clinical 
research, including the development and validation of 
risk prediction models.11 12 16 The primary care data are 
linked at individual patient level to Hospital Episode 
Statistics (HES) and to mortality records from the Office 
for National Statistics (ONS). HES provides details of all 
National Health Service (NHS) inpatient admissions 
since 1997, including primary and secondary causes 
coded using the ICD-10 (international classification of 
diseases, 10th revision) classifications and operations 
and procedures coded using the fourth revision of the 
Office of Population, Censuses and Surveys Classifica-
tion of Surgical Operations and Procedures (OPCS-4). 
ONS provides details of all deaths in England with pri-
mary and underlying causes, also coded using the ICD-
10 classification. Patients’ records are linked using a 
project specific pseudonymised NHS number, which is 
valid and complete for 99.8% of primary care patients, 
99.9% of ONS mortality records, and 98% of hospital 
admissions records.1
We included all QResearch practices in England that 
had been using their Egton Medical Information Sys-
tems (EMIS) computer system for at least a year. The 
EMIS computer system is the predominant commercial 
system used by 55% of family doctors in the United 
Kingdom for routine recording of health data for indi-
vidual patients (www.emishealth.com/). We randomly 
allocated three quarters of these practices to the deriva-
tion dataset and the remaining quarter to a validation 
dataset. In both datasets, we identified open cohorts of 
patients aged 25-84 years registered with eligible prac-
tices between 1 January 1998 and 31 July 2014. We then 
selected patients with diabetes if they had a Read code 
for diabetes or more than one prescription for insulin or 
oral hypoglycaemics. We classified patients as having 
type 1 diabetes if their diabetes had been diagnosed 
before they were 35 years of age and was treated with 
insulin;17 we classified all remaining patients as having 
type 2 diabetes. We excluded patients without a post-
code related deprivation score. We determined an entry 
date to the cohort for each patient, which was the latest 
of the date of diagnosis of diabetes, 25th birthday, date 
of registration with the practice plus one year, date on 
which the practice computer system was installed plus 
one year, and the beginning of the study period (1 Janu-
ary 1998). Patients were censored at the earliest date of 
the diagnosis of the relevant complication (blindness or 
lower limb amputation), death, de-registration with the 
practice, last upload of computerised data, or the study 
end date (1 August 2014).
We did an external validation using general practices 
in England contributing to the CPRD database. This is a 
similar database to QResearch except that it is derived 
from practices using a different clinical computer sys-
tem. We used the subset of 357 CPRD practices linked to 
ONS mortality and hospital admission data. We used 
the same definitions for selecting a validation cohort as 
for QResearch, except that the study end date was 1 
August 2012, the latest date for which linked data were 
available.
outcomes
We had two outcomes of interest: lower limb amputa-
tion based on a recorded diagnosis or procedure 
(including above knee and below knee amputations) 
and blindness (including blindness in one or both 
eyes, registered blind, severe visual impairment). We 
classified patients as having the outcome if a record of 
the relevant diagnosis was present in their primary 
care record, their linked hospital record, or the ONS 
mortality record. We used Read codes to identify 
recorded diagnoses from the primary care record. We 
used ICD-10 clinical codes and OPCS-4 procedure 
codes to identify incident cases of each outcome from 
hospital records.18 We used ICD-10 codes to identify 
cases from either the primary or underlying cause of 
death as recorded on the linked ONS mortality record. 
The web appendix gives a list of the Read codes, 
OPCS-4, and ICD-10 codes used. We used the earliest 
recorded date of the relevant diagnosis or procedure 
on any of the three data sources as the index date for 
the diagnosis. Patients with lower limb amputation at 
baseline were excluded from the cohort for the analy-
ses of lower limb amputations during follow-up and 
similarly for blindness.
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predictor variables
We examined the following predictor variables based 
on established risk factors for vascular disease:1  6 11 19-21 
age at cohort entry (continuous),22 type of diabetes 
(type 1 or type 2),2 number of years since diagnosis of 
diabetes (<1, 1-3, 4-6, 7-10, ≥11 years), smoking status 
(non-smoker; ex-smoker; light (1-9 cigarettes/day), 
moderate (10-19/day), heavy (≥20/day) smoker),22 
 ethnic group (white/not recorded, Indian, Pakistani, 
 Bangladeshi, other Asian, black Caribbean, black 
 African, Chinese, other),19 Townsend deprivation 
score  (continuous),11 21 glycated haemoglobin (HbA1c 
mmol/mol, continuous),1 22-24  systolic blood pressure 
(mm Hg, continuous),6 22 body mass index (kg/m2, 
 continuous), total serum cholesterol/high density 
 lipoprotein cholesterol ratio (continuous),11 atrial 
 fibrillation,11 congestive cardiac failure, cardiovascular 
disease, treated hypertension,11  peripheral vascular 
disease,21 chronic renal disease, rheumatoid arthritis,11 
and proliferative retinopathy or maculopathy.
For each of the continuous clinical variables, we used 
the value recorded closest to the baseline cohort entry 
date out of all those recorded before the baseline date or 
within the six months after this date. All other predictor 
variables were based on the latest information recorded 
in the primary care record before entry to the cohort. 
The United Kingdom now uses the SI unit of millimoles 
of HbA1c per mole of haemoglobin (mmol/mol) instead 
of the percentage.25  We converted historical values 
recorded in percentages to mmol/mol.26
derivation of models
We used established methods to develop risk predic-
tion equations for lower limb amputation and blind-
ness in the derivation cohort.11 12 We derived separate 
equations for men and women. Initially, we used com-
plete case analyses to derive fractional polynomial 
terms to model non-linear risk relations with continu-
ous variables if appropriate (age, body mass index, 
systolic blood pressure, serum cholesterol/high den-
sity lipoprotein ratio, HbA1c).27  We then used multiple 
imputation to replace missing values for continuous 
values and smoking status and used these values in 
our main analyses.28-30 We included all the candidate 
predictor variables listed above in the multiple impu-
tation models, along with the log of survival time and 
the censoring indicator. We log transformed body 
mass index, HbA1c, cholesterol, and high density lipo-
protein cholesterol before imputation, as they had 
positively skewed distributions. We carried out 10 
imputations to improve the statistical efficiency of the 
estimates.31  We used Cox’s proportional hazards mod-
els to estimate the coefficients for each risk factor for 
both of our outcomes by using the fractional polyno-
mial terms obtained from the complete case analyses. 
We used Rubin’s rules to combine the regression coef-
ficients across the imputed datasets.32 We fitted full 
models initially and then retained variables if they 
had a hazard ratio below 0.80 or above 1.20 (for binary 
variables) and were statistically significant at the 0.05 
level. We examined interactions between predictor 
 variables and age and included these if they were 
 significant and plausible (that is, similar in direction 
for both men and women and consistent with the liter-
ature) and they improved model fit. We assessed 
model fit by measuring the Akaike information crite-
rion and bayesian information criterion values for 
each imputed set of data.
We used the regression coefficients for each variable 
from the final model as weights, which we combined 
with the baseline survivor function evaluated up to 15 
years to derive risk equations over a period of 15 years of 
follow-up.33 This enabled us to derive absolute risk esti-
mates for each year of follow-up, with a specific focus 
on 10 year risk estimates. We estimated the baseline 
survivor function on the basis of zero values of centred 
continuous variables, with all binary predictor values 
set to zero.
Validation of models
We used multiple imputation in the two validation 
cohorts to replace missing values for continuous vari-
ables and smoking status. We carried out 10 imputa-
tions. We applied the risk equations for men and 
women obtained from the derivation cohort to the vali-
dation cohorts and calculated measures of discrimina-
tion. We calculated R2 values (explained variation in 
time to diagnosis of outcome),34  D statistics (a measure 
of discrimination for which higher values indicate bet-
ter discrimination),35  and Harrell’s C statistics (an 
extension of the receiver operating characteristic statis-
tic to survival data)36 over 10 years and combined these 
model performance measures across imputed datasets 
by using Rubin’s rules. We assessed calibration, com-
paring the mean predicted risks at 10 years with the 
observed risk by 10th of predicted risk. The observed 
risks were obtained using Kaplan-Meier estimates eval-
uated at 10 years. We applied the risk equations to the 
validation cohorts to define thresholds for the 10% and 
20% of patients at the highest estimated risk at 10 years 
and calculated sensitivity, specificity, and observed 
risks for these thresholds. 
We used all the available data for eligible patients on 
each database to maximise power and generalisability. 
We used Stata (version 13.1) for all analyses. We adhered 
to the TRIPOD statement for reporting.37
patient involvement
Patients were not involved in setting the research ques-
tion, the outcome measures, or the design or implemen-
tation of the study. Patient representatives from the 
QResearch Advisory Board have written the information 
for patients on the QResearch website about the use of 
the database for research. They have also advised on 
dissemination, including the use of lay summaries 
describing the research and its results.
Results
overall study population
Overall, 1017 QResearch practices in England met our 
inclusion criteria, of which 763 were randomly assigned 
to the derivation dataset; the remaining 254 practices 
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were assigned to the validation cohort. We identified 
455 551 patients aged 25-84 years with diabetes in the der-
ivation cohort. We excluded 976 (0.21%) patients without 
a recorded Townsend deprivation score, leaving 454 575 
for the derivation analysis. We identified 142 718 patients 
aged 25-84 years with diabetes in the QResearch valida-
tion cohort. We excluded 299 (0.21%) patients without a 
recorded Townsend deprivation score, leaving 142 419 for 
validation analysis. We identified 206 050 patients aged 
25-84 years with diabetes in the CPRD validation cohort 
from the 357 practices with linked Townsend scores and 
hospital admissions and mortality data.
Baseline characteristics
Table 1 shows baseline characteristics of 454 575 
patients with diabetes in the derivation cohort at 
table 1 | Baseline characteristics of patients with diabetes aged 25-84 years in qresearch derivation cohort and both validation cohorts. Values are 
numbers (percentages) unless stated otherwise
Characteristics
qresearch derivation cohort qresearch validation cohort Cprd validation cohort
women (n=199 679) Men (n=254 896) women (n=62 407) Men (n=80 012) women (n=90 280) Men (n=115 770)
Type 2 diabetes 188 086 (94.2) 241 058 (94.6) 58 852 (94.3) 75 717 (94.6) 85 361 (94.6) 109 540 (94.6)
Type 1 diabetes 11 593 (5.8) 13 838 (5.4) 3555 (5.7) 4295 (5.4) 4919 (5.4) 6230 (5.4)
Years since diagnosis:
 Newly diagnosed (<1 year) 108 040 (54.1) 137 725 (54.0) 34 900 (55.9) 44 412 (55.5) 48 913 (54.2) 62 922 (54.4)
 1-3 years 33 256 (16.7) 43 790 (17.2) 9819 (15.7) 12 902 (16.1) 14 912 (16.5) 19 345 (16.7)
 4-6 years 18 826 (9.4) 23 855 (9.4) 5552 (8.9) 7159 (8.9) 8283 (9.2) 10 535 (9.1)
 7-10 years 15 895 (8.0) 19 950 (7.8) 4824 (7.7) 6256 (7.8) 7285 (8.1) 9255 (8.0)
 >10 years 23 662 (11.9) 29 576 (11.6) 7312 (11.7) 9283 (11.6) 10 887 (12.1) 13 713 (11.8)
Mean (SD) age, years 61.5 (14.1) 59.5 (13.4) 62 (14.0) 59.9 (13.3) 62.7 (13.7) 60.4 (12.9)
Mean (SD) Townsend score 0.8 (3.4) 0.5 (3.4) 0.4 (3.3) 0.1 (3.2) 0 (3.3) −0.4 (3.2)
Ethnicity recorded: 150 526 (75.4) 191 204 (75.0) 46 575 (74.6) 59 394 (74.2) 40 151 (44.5) 51 522 (44.5)
 White/not recorded 164 366 (82.3) 214 557 (84.2) 53 760 (86.1) 70 000 (87.5) 83 962 (93.0) 108 518 (93.7)
 Indian 6836 (3.4) 9027 (3.5) 1928 (3.1) 2606 (3.3) 1503 (1.7) 2036 (1.8)
 Pakistani 5011 (2.5) 5744 (2.3) 854 (1.4) 1071 (1.3) 778 (0.9) 801 (0.7)
 Bangladeshi 5979 (3.0) 6731 (2.6) 956 (1.5) 1028 (1.3) 268 (0.3) 321 (0.3)
 Other Asian 3134 (1.6) 4017 (1.6) 1005 (1.6) 1393 (1.7) 865 (1.0) 1083 (0.9)
 Caribbean 5614 (2.8) 4653 (1.8) 1578 (2.5) 1291 (1.6) 919 (1.0) 768 (0.7)
 Black African 3831 (1.9) 4654 (1.8) 1004 (1.6) 1102 (1.4) 838 (0.9) 891 (0.8)
 Chinese 693 (0.3) 719 (0.3) 193 (0.3) 222 (0.3) 138 (0.2) 168 (0.1)
 Other 4215 (2.1) 4794 (1.9) 1129 (1.8) 1299 (1.6) 1009 (1.1) 1184 (1.0)
Smoking status recorded: 189 827 (95.1) 243 379 (95.5) 59 409 (95.2) 76 617 (95.8) 89 107 (98.7) 114 577 (99.0)
 Non-smoker 118 807 (59.5) 108 368 (42.5) 36 291 (58.2) 33 839 (42.3) 43 414 (48.1) 40 977 (35.4)
 Ex-smoker 41 073 (20.6) 83 683 (32.8) 13 572 (21.7) 27 231 (34.0) 14 002 (15.5) 28 100 (24.3)
 Light smoker 16 090 (8.1) 30 116 (11.8) 5112 (8.2) 9080 (11.3) 4879 (5.4) 7799 (6.7)
 Moderate smoker 7720 (3.9) 10 684 (4.2) 2512 (4.0) 3196 (4.0) 9772 (10.8) 12 756 (11.0)
 Heavy smoker 6137 (3.1) 10 528 (4.1) 1922 (3.1) 3271 (4.1) 5931 (6.6) 11 363 (9.8)
 Amount smoked not recorded NA NA NA NA 11 109 (12.3) 13 582 (11.7)
Medical conditions at baseline:
 Atrial fibrillation 7995 (4.0) 11009 (4.3) 2684 (4.3) 3626 (4.5) 3952 (4.4) 5273 (4.6)
 Congestive cardiac failure 6783 (3.4) 9986 (3.9) 2255 (3.6) 3136 (3.9) 3504 (3.9) 4641 (4.0)
 Cardiovascular disease 31 729 (15.9) 55 262 (21.7) 10 170 (16.3) 17 453 (21.8) 16 188 (17.9) 26 826 (23.2)
 Treated hypertension 78 323 (39.2) 85 634 (33.6) 24 451 (39.2) 26 721 (33.4) 31 477 (34.9) 32 465 (28.0)
 Peripheral vascular disease 5242 (2.6) 10 380 (4.1) 1692 (2.7) 3257 (4.1) 2846 (3.2) 5344 (4.6)
 Chronic renal disease 2325 (1.2) 2857 (1.1) 718 (1.2) 905 (1.1) 930 (1.0) 1185 (1.0)
 Rheumatoid arthritis 7458 (3.7) 4651 (1.8) 2204 (3.5) 1477 (1.8) 1976 (2.2) 1206 (1.0)
  Proliferative retinopathy or 
maculopathy
5531 (2.8) 7657 (3.0) 1653 (2.6) 2162 (2.7) 1319 (1.5) 1913 (1.7)
 Existing blindness 3416 (1.7) 3701 (1.5) 1126 (1.8) 1169 (1.5) 1789 (2.0) 1656 (1.4)
 Existing lower limb amputation 1010 (0.5) 2073 (0.8) 346 (0.6) 728 (0.9) 455 (0.5) 1013 (0.9)
Clinical values at baseline:
 HbA1c recorded 141 005 (70.6) 180 594 (70.9) 43 575 (69.8) 56 107 (70.1) 51 725 (57.3) 67 013 (57.9)
 Mean (SD) HbA1c, mmol/mol 61.4 (20.8) 63 (22.0) 61.1 (20.8) 62.9 (21.9) 60.8 (21.1) 62.6 (22.0)
 Body mass index recorded 179 818 (90.1) 232 298 (91.1) 55 892 (89.6) 72 979 (91.2) 82 814 (91.7) 107 778 (93.1)
 Mean (SD) body mass index 31.1 (6.3) 29.8 (5.3) 31.2 (6.4) 29.9 (5.3) 30.9 (6.3) 29.7 (5.3)
 Cholesterol ratio recorded 105 436 (52.8) 138 385 (54.3) 33 392 (53.5) 43 988 (55.0) 35 174 (39.0) 46 530 (40.2)
  Mean (SD) cholesterol/high density 
lipoprotein cholesterol ratio
4.1 (1.4) 4.5 (1.5) 4.1 (1.4) 4.5 (1.5) 4.2 (1.5) 4.5 (1.6)
 Systolic blood pressure recorded 194 001 (97.2) 246 991 (96.9) 60 728 (97.3) 77 707 (97.1) 88 792 (98.4) 113 582 (98.1)
  Mean (SD) systolic blood 
pressure, mm Hg
139.3 (20.0) 138.4 (18.6) 139.8 (20.0) 138.6 (18.6) 141.4 (20.6) 140 (19.0)
NA=not applicable.
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study entry. Of these, 94% had type 2 diabetes. Just 
over half had been diagnosed as having diabetes less 
than a year before cohort entry, 17% had been diag-
nosed for 1-3 years, 9% for 4-6 years, 8% for 7-10 years, 
and 12% for 11 or more years. Smoking status was 
recorded in 95% of patients, ethnicity in 75%, body 
mass index in 90%, systolic blood pressure in 97%, 
HbA1c in 71%, and cholesterol/high density lipopro-
tein cholesterol ratio in 53%. Of the 454 575 patients in 
the derivation cohort, 266 142 (58.6%) had missing 
data for at least one of these variables (including 
 ethnicity).
Baseline characteristics for patients in the QResearch 
validation cohort were similar to corresponding values 
in the derivation cohort (table 1). Of the 142 419 patients 
in the QResearch validation cohort, 83 403 (58.6%) had 
missing data for at least one variable. Baseline charac-
teristics of the CPRD validation cohort were also similar, 
except that the recording of ethnicity (45%), choles-
terol/high density lipoprotein cholesterol ratio (40%), 
and HbA1c (58%) was substantially lower in CPRD than 
in QResearch. Of the 206 050 patients in the CPRD vali-
dation cohort, 166 648 (80.9%) had missing data for at 
least one variable.
primary outcomes of amputation and blindness
Table 2 shows the number of incident cases of each out-
come during follow-up and the age standardised inci-
dence rates in each cohort. In the QResearch derivation 
cohort, 4822 cases of amputation and 8063 cases of 
blindness occurred. In addition, 1524 cases of amputa-
tion and 2651 cases of blindness occurred in the QRe-
search validation cohort, and 2294 cases of amputation 
and 2845 cases of blindness occurred in the CPRD vali-
dation cohort. The rate of blindness was lower in men in 
CPRD (2.33 per 1000 person years) than in both QRe-
search cohorts (3.03 per 1000 person years) and was also 
lower in women in CPRD, but rates of amputation were 
similar.
predictor variables
Table 3 shows the adjusted hazard ratios for variables in 
the final models for men and women in the derivation 
cohort.
Lower limb amputation
The final model for lower limb amputation in women 
included age, systolic blood pressure, HbA1c, depriva-
tion, duration of diabetes, smoking status, ethnicity, 
rheumatoid arthritis, congestive cardiac failure, 
peripheral vascular disease, and chronic renal dis-
ease. The final model in men also included type of 
diabetes and atrial fibrillation. Body mass index and 
the serum cholesterol/high density lipoprotein cho-
lesterol ratio were not significantly associated with 
risk in men or women. Increasing duration of diabetes 
was associated with an increased risk of lower limb 
amputation in men and women. Increasing levels of 
smoking were associated with an increased risk of 
amputation; the association was more marked in 
women than in men. For heavy smokers compared 
with non-smokers, a 1.9-fold increase in risk of ampu-
tation was seen for women and a 1.3-fold increased 
risk for men. South Asian ethnic groups had a lower 
risk compared with people whose ethnic group was 
either white or not recorded; Caribbean and black 
African men also had lower risks. Pre-existing periph-
eral vascular disease was associated with the highest 
risks (fourfold in women and threefold in men), 
 followed by chronic renal disease (2.7-fold in women 
and 2.3-fold in men).
Figs 1-3 show adjusted hazard ratios for age, HbA1c, 
and systolic blood pressure. Increasing values of age, 
HbA1c, and systolic blood pressure, were associated 
with an increased risk of lower limb amputation in men 
and women.
Blindness
The final models for blindness in men and women 
included age, cholesterol/high density lipoprotein 
cholesterol ratio, systolic blood pressure, HbA1c, 
deprivation, duration of diabetes, type of diabetes, 
chronic renal disease, and existing proliferative ret-
inopathy or maculopathy. Body mass index and 
smoking status were not significantly associated 
with risk. Increasing values of age, HbA1c, and sys-
tolic blood pressure were associated with an 
increased risk of blindness (figs 1-3). Increasing val-
ues of the serum cholesterol/high density lipopro-
tein cholesterol ratio were also associated with an 
increased risk of blindness. Increasing duration of 
diabetes was associated with increased risk despite 
adjustment for age and other risk factors. We found 
a  significant interaction between renal disease and 
age. Pre-existing proliferative  retinopathy or 
 maculopathy was the strongest risk  factor, with a 
2.7-fold increase for women and a 2.9-fold increase 
for men.
Web calculator
The web calculator that implements the risk equations 
for the final models can be found at qdiabetes.org/
amputation-blindness/index.php, along with the open 
source software which includes the equations (pub-
lished separately, as these will be updated over time as 
newer data becomes available).
table 2 | numbers of incident cases* of blindness and lower limb amputation during 
follow-up and age standardised incidence rates per 1000 person years in men and 
women with diabetes aged 25-84 years in derivation cohort and validation cohorts
qresearch derivation 
cohort
qresearch validation 
cohort Cprd validation cohort
Cases
rate† per 1000 
person years 
(95% Ci) Cases
rate† per 1000 
person years 
(95% Ci) Cases
rate† per 1000 
person years 
(95% Ci)
women
Amputation 1541 1.34 (1.27 to 1.41) 482 1.32 (1.20 to 1.44) 675 1.32 (1.22 to 1.42)
Blindness 4074 3.43 (3.33 to 3.54) 1365 3.59 (3.40 to 3.79) 1487 2.78 (2.64 to 2.93)
Men
Amputation 3281 2.36 (2.28 to 2.44) 1042 2.33 (2.19 to 2.47) 1619 2.66 (2.53 to 2.79)
Blindness 3989 3.03 (2.93 to 3.12) 1286 3.04 (2.88 to 3.21) 1358 2.33 (2.20 to 2.45)
*Patients with existing diagnoses of each complication at baseline were dropped from relevant cohort.
†Rates were directly age standardised to overall age distribution of patients aged 25-84 within QResearch 
derivation cohort in 5 year age bands.
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Validation
Discrimination
Table 4 shows the performance of each equation in both 
validation cohorts. For men in the CPRD cohort, the 
equations explained 40.6% of the variation in time to 
diagnosis of amputation and 31.9% for blindness, and 
discrimination was good for amputation (D  statistic 
1.69, Harrell’s C statistic 0.77) and blindness (D statistic 
1.40, Harrell’s C statistic 0.73). The results for women in 
the CPRD cohort were very similar to those for men. The 
results for both sexes in the CPRD cohort were similar to 
those for the QResearch validation cohort, although the 
point estimates for CPRD tended to be marginally 
higher.
table 3 | adjusted hazard ratios for blindness and lower limb amputation in men and 
women in derivation cohort
Characteristic
adjusted hazard ratio (95%Ci)
women Men
amputation*
Townsend deprivation score† 1.10 (1.01 to 1.19 ) 1.29 (1.22 to 1.36 )
Duration of diabetes:
 Newly diagnosed (<1 year) 1 1
 1-3 years 1.59 (1.36 to 1.85 ) 1.68 (1.51 to 1.87 )
 4-6 years 1.69 (1.42 to 2.01 ) 2.03 (1.81 to 2.28 )
 7-10 years 2.37 (2.01 to 2.79 ) 2.67 (2.39 to 3.00 )
 >10 years 3.30 (2.89 to 3.78 ) 3.49 (3.15 to 3.86 )
Smoking status:
 Non-smoker 1 1
 Ex-smoker 1.08 (0.94 to 1.24 ) 0.94 (0.87 to 1.03 )
 Light smoker 1.59 (1.34 to 1.88 ) 1.28 (1.14 to 1.43 )
 Moderate smoker 1.58 (1.25 to 1.99 ) 1.15 (0.96 to 1.37 )
 Heavy smoker 1.89 (1.49 to 2.41 ) 1.26 (1.06 to 1.49 )
Ethnicity:
 White/not recorded 1 1
 Indian 0.44 (0.28 to 0.68 ) 0.42 (0.32 to 0.55 )
 Pakistani 0.72 (0.47 to 1.12 ) 0.40 (0.28 to 0.58 )
 Bangladeshi 0.29 (0.15 to 0.56 ) 0.12 (0.07 to 0.22 )
 Other Asian 0.70 (0.39 to 1.27 ) 0.42 (0.26 to 0.67 )
 Caribbean 0.87 (0.65 to 1.18 ) 0.49 (0.36 to 0.66 )
 Black African 0.92 (0.55 to 1.54 ) 0.38 (0.23 to 0.61 )
 Chinese 0.50 (0.12 to 1.99 ) 0.35 (0.11 to 1.09 )
 Other 0.70 (0.44 to 1.10 ) 0.63 (0.45 to 0.87 )
Comorbidity:
 Type 1 diabetes (versus type 2) NS 1.26 (1.09 to 1.45 )
 Rheumatoid arthritis 1.50 (1.19 to 1.90 ) 1.39 (1.11 to 1.75 )
 Atrial fibrillation NS 1.26 (1.07 to 1.49 )
 Congestive cardiac failure 1.79 (1.44 to 2.22 ) 1.34 (1.14 to 1.58 )
 Peripheral vascular disease 4.26 (3.63 to 4.99 ) 3.16 (2.84 to 3.51 )
 Chronic renal disease 2.68 (1.96 to 3.66 ) 2.26 (1.80 to 2.85 )
Blindness‡
Cholesterol/HDL ratio§ 1.06 (1.03 to 1.09 ) 1.03 (1.00 to 1.06 )
Townsend deprivation score† 1.21 (1.15 to 1.27 ) 1.33 (1.27 to 1.39 )
Duration of diabetes:
 Newly diagnosed (<1 year) 1 1
 1-3 years 1.36 (1.25 to 1.49 ) 1.40 (1.28 to 1.54 )
 4-6 years 1.51 (1.36 to 1.67 ) 1.42 (1.28 to 1.58 )
 7-10 years 1.72 (1.55 to 1.91 ) 1.57 (1.41 to 1.76 )
 >10 years 2.17 (1.97 to 2.38 ) 2.09 (1.90 to 2.29 )
Comorbidity:
 Type 1 diabetes (versus type 2) 1.50 (1.26 to 1.78 ) 1.44 (1.22 to 1.70 )
 Chronic renal disease 1.49 (1.17 to 1.89 ) 2.57 (1.88 to 3.52 )
 Proliferative retinopathy/maculopathy 2.67 (2.37 to 3.02 ) 2.93 (2.61 to 3.29 )
HDL=high density lipoprotein cholesterol; NS=not significant.
*Amputation model in women also included terms for age (linear), systolic blood pressure (2 fractional 
polynomial (FP) terms: −1, −0.5), HbA1c (2 FP terms: 3, 3); amputation model in men included terms for age 
(linear), systolic blood pressure (2 FP terms: −2, 0.5), HbA1c (2 FP terms: 2, 2).
†Townsend deprivation score ranges between −7 (most affluent) and 11 (most deprived); adjusted hazard ratio is 
per 5 unit increase. 
‡Blindness model in women also included terms for age (2 FP terms: 2, 2), systolic blood pressure (linear), HbA1c 
(2 FP terms: 2, 2); model in men also included terms for age (2 FP terms: 2, 2), systolic blood pressure (2 FP terms: 
1, 2), HbA1c (2 FP terms: −2, −2); there was an interaction between age and renal disease in men.
§Adjusted hazard ratio is per unit increase.
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Calibration
Figure 4  shows the mean predicted and observed risks 
of both outcomes at 10 years by 10th of predicted risk, 
applying the equations to men and women in the QRe-
search validation cohort. Figure 5 shows comparable 
results for the CPRD cohort. We found close correspon-
dence between the mean predicted risks and the 
observed risks within each model 10th, indicating that 
the equations were well calibrated across both valida-
tion cohorts.
Performance at threshold for 10% and 20% 
of patients at highest risk
Table 5 shows the sensitivity, specificity, and observed 
risk for the 10% and 20% of men and women at the 
highest predicted risk of each outcome for both valida-
tion cohorts for illustrative purposes. For example, 
when we used a 10 year risk threshold of 3.2% for ampu-
tation in men in CPRD to identify the 20% at highest 
predicted risk, the sensitivity was 58%, the specificity 
was 80.5%, and the observed risk was 7%.
implementation
Figure 6 shows a clinical example of the implementation 
of the equations using the web calculator (qdiabetes.
org/amputation-blindness/index.php). The example is 
for a 50 year old female non-smoker with newly diag-
nosed type 2 diabetes and an HbA1c of 65 mmol/mol, a 
cholesterol/high density lipoprotein cholesterol ratio 
of 2, and a systolic blood pressure of 140 mm Hg. Her 
10 year risk of blindness is 1%, and her risk of amputa-
tion is 0.5%.
Figure 7 shows the results for a 75 year old man, diag-
nosed as having type 2 diabetes 10 years ago, who is a 
moderate smoker and has chronic kidney disease, an 
HbA1c of 70 mmol/mol, a cholesterol/high density lipo-
protein cholesterol ratio of 4, and a systolic blood pres-
sure of 160 mm Hg. His 10 year risk of blindness is 
14.7%, and his risk of amputation is 12.1%.
discussion
We have developed and externally validated risk predic-
tion equations to quantify the absolute risks of blind-
ness and lower limb amputation over 10 years in men 
and women with type 1 and type 2 diabetes. The 
 equations are well calibrated and have good discrimi-
nation, with C statistic values of at least 0.73 in the 
external CPRD validation cohort. To our knowledge, 
these are the first tools for predicting the 10 year risk of 
both blindness and amputation, two of the complica-
tions that most concern patients with diabetes and 
affect quality of life.
Clinical implications
These algorithms are designed to provide better 
information for patients and doctors on the absolute 
risks of blindness and amputation, to inform man-
agement decisions. Patients with diabetes tend to 
overestimate their risk of complications and also 
overestimate the benefits of treatment.10  For exam-
ple, in one study, patients believed that they were 1.5 
times more likely to become blind and 13 times more 
likely to have a lower leg amputation than estimates 
of absolute risk based on the DCCT trial.2 10  Some 
people may argue that overestimating the risk of 
complications might result in patients being more 
likely to take intensive treatment. However, from a 
holistic and ethical point of view, more accurate indi-
vidualised information on the risk of complications 
table 4 | performance of equations in men and women in Cprd validation cohort and 
qresearch validation cohort
Statistic
Mean (95% Ci)
Cprd validation cohort
qresearch validation 
cohort
women
Amputation:
 D statistic* 1.61 (1.45 to 1.77 ) 1.30 (1.14 to 1.47 )
 R2 (%)† 38.22 (33.61 to 42.83 ) 28.90 (23.70 to 34.10 )
 Harrell’s C statistic‡ 0.762 (0.735 to 0.789) 0.700 (0.670 to 0.731)
Blindness:
 D statistic* 1.36 (1.27 to 1.46 ) 1.32 (1.23 to 1.42 )
 R2 (%)† 30.78 (27.94 to 33.63 ) 29.44 (26.50 to 32.39 )
 Harrell’s C statistic‡ 0.733 (0.719 to 0.747) 0.725 (0.709 to 0.741)
Men
Amputation:
 D statistic* 1.69 (1.59 to 1.79 ) 1.48 (1.38 to 1.59 )
 R2 (%)† 40.57 (37.70 to 43.44 ) 34.42 (31.14 to 37.70 )
 Harrell’s C statistic‡ 0.770 (0.755 to 0.784) 0.748 (0.730 to 0.767)
Blindness:
 D statistic* 1.40 (1.31 to 1.49 ) 1.33 (1.23 to 1.42 )
 R2 (%)† 31.93 (29.04 to 34.82 ) 29.57 (26.53 to 32.62 )
 Harrell’s C statistic‡ 0.732 (0.716 to 0.747) 0.714 (0.696 to 0.731)
*A measure of discrimination that is specific to censored survival data for which higher values indicate better 
discrimination.
†Measures explained variation in time to diagnosis of outcome; higher values indicate that more variation is 
explained.
‡A measure of discrimination for which higher values indicate better discrimination.
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may help patients to make more informed decisions 
about the balance of risks and benefits of treatment 
options reflecting their own values and choices. 
Overestimation of the risk of complications might 
lead to increased levels of anxiety and depression, 
which could negatively affect quality of life. This is 
especially important as patients with diabetes are 
more likely than the general population to experi-
ence anxiety and depression.38
For clinicians and the health service, more accurate 
methods for stratifying patients according to their 
absolute risk of complications could enable screening 
programmes to be tailored to an individual’s level of 
risk and support the more rational use of scarce 
resources. For example, blindness can be prevented by 
screening for and treatment of retinopathy,39  and 
patients at high risk of blindness might need retinal 
screening more often than once a year. Those at higher 
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risk of amputation might benefit from a proactive tar-
geted programme to prevent lower extremity amputa-
tion (including more frequent checks, tailored patient 
education, specially designed protective footwear, and 
early reporting of foot injuries), as this has been shown 
to substantially reduce the risk of emergency admis-
sions, use of antibiotics, foot operations, and lower 
limb amputation compared with usual practice.40  41 
Better information on the absolute risk of individual 
complications could also prompt more intensive treat-
ment of modifiable risk factors—such as lowering of 
HbA1c and tighter blood pressure control—which are 
generally considered to reduce the risk of microvascu-
lar complications such as blindness.2 5 42
Comparisons with literature
The incidence rates of amputation and blindness are 
comparable to the amputation rate of 1.6 per 1000 
patient years and blindness rate of 3.5 per 1000 patient 
years reported by the UKPDS.5  However, our study is 
approximately 100-fold larger than the UKPDS, with 
almost 5000 incident amputations and more than 8000 
cases of recorded blindness in the derivation cohort, 
and it is 10 times larger than the US hospital based 
cohort study reported by Zhao et al.24  Our study is also 
more recent than the UKPDS, which started almost 40 
years ago and ended almost 20 years ago.5 Our study 
included patients with prevalent type 1 and type 2 dia-
betes as well as those with a new diagnosis, enabling us 
to account for the important contribution of duration of 
diabetes to risk and to ensure that the results can be 
applied to patients with either newly diagnosed or prev-
alent diabetes.
We included established risk factors in our equa-
tions and report hazard ratios similar in both magni-
tude and direction to those reported elsewhere for 
lower limb amputation,1  progression of retinopathy, 
and blindness,1 20  which increases the clinical face 
validity of the equations. As in the UKPDS,6  increased 
systolic blood pressure was associated with increased 
risks of blindness and lower limb amputation,20 and 
increased levels of HbA1c were associated with 
increased risks of blindness and amputation when 
compared over equivalent ranges.1 24  Deprivation and 
smoking were associated with an increased risk of 
amputation in our study and others.21  However, smok-
ing was not associated with an increased risk of blind-
ness in our study, which is consistent with other 
research.20  Non-white ethnic groups had lower risks of 
lower limb amputation compared with the white group. 
This contrasts with a US study in which black Africans 
had a higher risk of amputation.19
Three economic models have been based on the 
DCCT and UKPDS studies.2  5  The CORE diabetes and 
Sheffield diabetes models are based on equations 
derived from the DCCT trial and the UKPDS study.43-45 
The EAGLE model is based on equations derived from 
UKPDS and the DCCT, as well as the Wisconsin Epide-
miological Study of Diabetic Retinopathy.46  The CORE 
model predicts risk of amputation,46 and the CORE, 
EAGLE, and Sheffield models predict retinopathy rather 
than blindness.
Methodological considerations
The methods used to derive and validate these models 
are very similar to those for other risk prediction tools 
derived from the QResearch database, the strengths and 
limitations of which have been discussed in detail.11 12 
In summary, key strengths include cohort size, duration 
table 5 | performance of each model in both qresearch and Cprd validation cohorts based on 10% and 20% of patients at highest predicted risk
qresearch cohort Cprd cohort
Cut-off (%) for 
10 year risk* Sensitivity (%) Specificity (%)
observed 
risk (%)
Cut-off (%) for 
10 year risk* Sensitivity (%) Specificity (%) observed risk (%)
women
Amputation (top 10%) 2.6 33.2 90.2 4.6 2.9 39.4 90.2 4.9
Amputation (top 20%) 1.8 48.1 80.2 3.2 2.0 59.8 80.3 3.7
Blindness (top 10%) 8.1 27.9 90.4 12.8 8.0 25.7 90.2 8.7
Blindness (top 20%) 5.6 45.1 80.5 9.6 5.6 44.3 80.4 7.2
Men
Amputation (top 10%) 4.5 37.5 90.3 7.9 4.8 41.9 90.4 10.2
Amputation (top 20%) 3.0 53.5 80.4 5.7 3.2 58.0 80.5 7.0
Blindness (top 10%) 6.2 27.6 90.2 9.5 6.0 31.5 90.2 8.3
Blindness (top 20%) 4.1 45.9 80.4 7.2 4.1 49.1 80.3 6.1
*Risk threshold for 10% or 20% of patients at highest predicted risk of outcome over 10 years.
Fig 6 | web calculator applied to example female patient
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of follow-up, representativeness, and lack of selection, 
recall, and respondent bias. UK general practices have 
good levels of accuracy and completeness in recording 
clinical diagnoses and prescribed drugs.47 The QRe-
search database has linked hospital and mortality 
records for almost all patients and is therefore likely to 
have picked up most cases of lower limb amputation, 
thereby minimising ascertainment bias. The QResearch 
database is updated regularly, allowing us to update the 
algorithms over time to reflect changes in data quality, 
population characteristics, or requirements, thereby 
keeping the tools up to date.
We undertook two validations, one using a separate 
set of practices and patients contributing to QRe-
search and the other using a fully external set of prac-
tices contributing to CPRD. The results of both 
validations were extremely similar, which is consis-
tent with previous validation studies showing compa-
rable performance using different practice 
populations.48  49 Although we have derived and vali-
dated the equations using UK datasets, the equations 
could be used internationally by using alternative 
deprivation scores relevant to the setting (which 
would need to be scaled to conform with the 
Townsend score). Local validation should be done to 
ensure good calibration and discrimination in the 
applicable population, as patients from different 
countries may have different rates of complications or 
distributions of risk factors.
Limitations of our study include the lack of formal 
adjudication of diagnoses and the potential for bias 
due to missing data, which we have addressed using 
multiple imputation. Although we have provided anal-
ysis of several thresholds for illustrative purposes, we 
have not provided definite comment on what threshold 
of absolute risk should be used to define a “high risk” 
group, as that would require consideration of the bal-
ance of risks and benefits for individuals and cost 
 effectiveness analyses, which are outside the scope of 
this study.
Conclusion
We have developed and validated new risk prediction 
equations to quantify the absolute risks of blindness 
and lower limb amputation in patients with diabetes. 
They can be used to identify patients with diabetes at 
high risk of these complications for further assessment. 
Further research is needed to evaluate the clinical out-
comes and cost effectiveness of using these risk equa-
tions in primary care.
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